Sep 26, 2026

Biomea Fusion Inc. (BMEA) stock fell by over 10% after the company initially announced, then quickly terminated, an underwritten stock and warrant offering due to unfavorable market conditions. The proposed offering aimed to fund clinical-stage diabetes and obesity programs, highlighting the company's ongoing need for cash. Analysts maintain a negative outlook on the early-stage biotech due to its cash-burning nature, lack of revenue, and high valuation based on pipeline optionality, with technical indicators showing a clear short-term downtrend.

Sep 25, 2026

Biomea Fusion Inc (NASDAQ: BMEA) shares dropped 18.82% in after-hours trading after the company announced an underwritten public offering of its common stock and pre-funded warrants. The clinical-stage diabetes and obesity medicines company did not disclose the terms or size of the offering, which is subject to market conditions. This announcement led to the significant share price decrease despite the company's positive price trend rankings.

Sep 23, 2026

Biomea Fusion (NASDAQ: BMEA) shares dropped by nearly 19% after the company terminated its proposed public offering of securities. Additionally, Biomea Fusion announced a delay in the topline results from its Phase I GLP-131 trial for BMF-650, which are now expected in October 2026 instead of the previously anticipated third quarter of 2026. The company had also added an extra cohort to the study in June to further optimize its weight reduction potential.

Sep 23, 2026

Biomea Fusion Inc. (NASDAQ: BMEA) shares dropped 18.82% in after-hours trading after the company announced an underwritten public offering of common stock and pre-funded warrants. The clinical-stage biopharmaceutical company, which is developing therapies for diabetes and obesity, did not disclose the terms or size of the offering. Biomea Fusion intends to grant the underwriter an option to purchase an additional 15% of the total shares and warrants.